title: Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.
authors.affiliation: Melanoma Institute Australia, Sydney, NSW, Australia.|The University of Sydney, Sydney, NSW, Australia.
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Menzies
authors.affiliation: Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Iwei
authors.initials: I
authors.lastname: Yeh
authors.affiliation: Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Botton
authors.affiliation: Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
authors.forename: Boris C
authors.initials: BC
authors.lastname: Bastian
authors.affiliation: Melanoma Institute Australia, Sydney, NSW, Australia.|The University of Sydney, Sydney, NSW, Australia.|Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Scolyer
authors.affiliation: Melanoma Institute Australia, Sydney, NSW, Australia.|The University of Sydney, Sydney, NSW, Australia.
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Long
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000556:secondary; D002352:Carrier Proteins / Q000378:metabolism; D004252:DNA Mutational Analysis; D018450:Disease Progression; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors*; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics; D008565:Membrane Proteins / Q000378:metabolism; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism*; D011728:Pyridones / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C568616:BRAF-KIAA1549 fusion protein, human; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D015514:Oncogene Proteins, Fusion; C559265:PPFIBP2 protein, human; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; C582435:pembrolizumab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020930:MAP Kinase Kinase Kinases